

PRINCIPLE OF THE METHOD

Amylase catalyzes the hydrolysis of 4-nitrophenyl-maltoheptaoside-ethylidene to smaller oligosacharides which are hydrolyzed by α -glucosidase liberating 4-nitrophenol. The catalytic concentration is determined from the rate of 4-nitrophenol formation, measured at 405 nm^{1,2}. Specific antibodies inhibits the salivary isoenzyme and thus allow the measurement of pancreatic α-amylase^{3,4}.

CONTENTS AND COMPOSITION

- A. Reagent: 1 x 20 mL. HEPES 50 mmol/L, calcium chloride 0.075 mmol/L, sodium chloride 90 mmol/L, magnesium chloride 13 mmol/L, α -glucosidase > 4 U/mL, pH 7.1, monoclonal antibodies (mouse) 50 mg/L.
- B. Reagent: 1 x 5 mL. HEPES 50 mmol/L, 4-Nitrophenyl-maltoheptaoside-ethylidene 18 mmol/L, pH 7.1.

STORAGE

Store at 2-8°C

Reagents are stable until the expiry date shown on the label when stored tightly closed and if contaminations are prevented during their use.

Indications of deterioration:

Reagents: Presence of particulate material, turbidity, absorbance of the blank over 0.300 at 405 nm (1 cm cuvette)

REAGENT PREPARATION

Reagents are provided ready to use.

ADDITIONAL EQUIPMENT

- Analyzer, spectrophotometer or photometer with cell holder thermostatable at 37°C and able to read at 405 nm.
- Cuvettes with 1 cm light path.

SAMPLES

Serum, plasma or urine collected by standard procedures.

Pancreatic α -amylase in serum or plasma is stable for 1 month at 2-8°C. Use heparin or EDTA

Pancreatic α -amylase in urine is stable for 1 month at 2-8°C if pH is adjusted to approximately 7 before storage. Centrifuge or filter before testing.

- 1. Bring the Reagent and the instrument to reaction temperature.
- 2. Pipette into a cuvette: (Notes 1,2)

	Serum or plasma	Urine
Reagent (A) Sample	0.8 mL 30 µL	0.8 mL 15 µL

3. Mix and insert the cuvette into the instrument. Start the stopwatch. After 3-5 minutes, add:

Reagent (B)	0.2 mL	0.2 mL

- 4. Mix
- 5. After 2 minutes, record initial absorbance at 405 nm and at 1 minute intervals thereafter for 3 minutes
- 6. Calculate the difference between consecutive absorbances, and the average absorbance difference per minute ($\Delta A/min$).

CALCULATIONS

Pancreatic α-amylase concentration in the sample is calculated using the following general formula:

$$\Delta A/\min x \frac{Vt \times 10^6}{\epsilon \times 1 \times Vs} = U/L$$

The molar absorbance (ϵ) of 4-nitrophenol at 405 nm is 10600 and the lightpath (I) is 1 cm. For serum and plasma samples, the total reaction volume (Vt) is 1.030 and the sample volume (Vs) is 0.030. For urine samples, the total reaction volume (Vt) is 1.015 and the sample volume (Vs) is 0.015. 1 U/L are 0.0166 μ kat/L. The following formulas are deduced for the calculation of the catalytic concentration:

ΔA/min	Serum, plasma	x 3239 = U/L x 53.8 = µkat/L
ΔΑ/ΠΙΙΙ	Urine	x 6384 = U/L x 105.9 = μkat/L

REFERENCE VALUES

Serum, plasma ⁵		Urine ⁵		
	U/L	μkat/L	U/L	µkat/L
	13-53	0.22-0.88	7-356	0.12-5.92

These ranges are given for orientation only; each laboratory should establish its own reference ranges

QUALITY CONTROL

It is recommended to use the Biochemistry Control Serum level I (cod. 18042), level II (cod. 18043) and the Biochemistry Control Urine (cod. 18054 and cod. 18066) to verify the performance of the measurement procedure.

Each laboratory should establish its own internal Quality Control scheme and procedures for corrective action if controls do not recover within the acceptable tolerances.

METROLOGICAL CHARACTERISTICS

- Detection limit: 6.7 U/L = 0.11 μkat/L.
- Linearity limit: 1300 U/L = 21.6 μ kat/L (serum and plasma) and 2600 U/L = 43.2 μ kat/L (urine). For higher values dilute sample 1/5 with distilled water and repeat measurement.
- Repeatibility (within run):

Serum. Mean Concentration	CV	n
62.4 U/L = 1.04 μkat/L	3.9 %	20
138 U/L = 2.29 μkat/L	1.1 %	20

Reproducibility (run to run):

Serum. Mean Concentration	CV	n
62.4 U/L = 1.04 μkat/L	4.3 %	25
138 U/L = 2.29 μkat/L	2.8 %	25

- Trueness: Results obtained with this reagent did not show systematic differences when compared with reference reagents. Details of the comparison experiments are available on request.
- Interferences: Hemoglobin (10 g/L) and bilirubin (20 mg/dL) do not interfere. Lipemia (triglycerides 30 g/L) interfere. Other drugs and substances may interfere

These metrological characteristics have been obtained using an analyzer. Results may vary if a different instrument or a manual procedure are used.

DIAGNOSTIC CHARACTERISTICS

 α -Amylase catalyzes the hydrolysis of α -1,4-linkages of carbohydrates constituted of α -Dglucose units. The result is the formation of dextrins, maltose and some glucose molecules, α -Amylase is produced mainly by the exocrine pancreas (P-type; P-AMY) and the salivary glands (S-type; S-AMY) but it is also found in other tissues. The enzyme present in normal serum and urine is predominantly of pancreatic and salivary gland origin.

Assays of α -amylase activity in serum and urine are largely of use in the diagnosis of pancreatic diseases such as acute or chronic pancreatitis. Hyperamylasemia can also be due to renal insufficiency, acute pain of the abdomen, tumors of the lungs and the ovaries, salivary glands lesions, macroamylasemia, diabetic ketoacidosis, biliary tract disease, cerebral trauma, chronic alcoholism and drugs (opiates). The lack of specificity of total α -amylase measurements has led to the interest in the direct measurement of pancreatic α -amylase instead of total enzyme activity for the differential diagnosis of patients with acute abdominal pain^{7,8}

Clinical diagnosis should not be made on the findings of a single test result, but should integrate both clinical and laboratory data.

- 1. Saliva and skin do contain α -amylase, therefore never pipette by mouth and avoid skin contact with the reagents.
- 2. This reagent may be used in several automatic analysers. Instructions for many of them are available on request.

BIBLIOGRAPHY

- 1. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37°C. Part 8. Reference procedure for the measurement of catalytic concentration of α-amylase. Clin Chem Lab Med 2006; 44: 1146-1155.
- 2. Lorentz K. Routine α -amylase assay using protected 4-nitrophenyl-1,4- α -D-maltoheptaoside and a novel α -glucosidase. Clin Chem 2000:46:644-649
- 3. Gerber M, Naujooks H, Lenz H, Wulff K. A monoclonal antibody that specifically inhibits human salivary α-amylase. Clin Chem. 1987;33:1158-62.4.
- 4. Steen G, Blijenberg BG, Leijnse B. Experiences with a new assay for pancreas specific alpha-amylase. Ann Biol Clin 1990;48(2):91-97.
- 5. Junge W, Werner W, Wilke B et al. Development and evaluation of assays for the determination of total and pancreatic amylase at 37 °C according to the principle recommended by the IFCC. Clin Biochem 2001;34:607-615.
- 6. Young DS. Effects of drugs on clinical laboratory tests, 5th ed. AACC Press, 2000.
- 7. Friedman and Young. Effects of disease on clinical laboratory tests, 4th ed. AACC Press, 2001
- 8. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th edition. Burtis CA, Ashwood ER. WB Saunders Co., 2005.

www.biosystems.global